Clinical Trials Browser

Withdrawn × Interventional × Peripheral Nervous System Diseases × Clear all

Breast Neoplasms, Peripheral Nervous System Diseases

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT02215083 2017-07-12

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT02168894 2016-03-08

SINF: Peripheral Neuropathy in Cancer Survivors

Phase 1/2 Withdrawn

Peripheral Nervous System Diseases

Clinical Trials

Evaluation of Hydroxychloroquine to Prevent CIPN

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

SINF: Peripheral Neuropathy in Cancer Survivors